Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Alopecia areata
  • Focus Therapeutic Use
  • Acronyms BRAVE-AA1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Dec 2018 Planned End Date changed from 25 Mar 2022 to 5 Aug 2022.
    • 19 Nov 2018 Planned End Date changed from 5 Aug 2022 to 25 Mar 2022.
    • 26 Sep 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top